The April 2026 DOJ final order, issued under President Trump’s executive directive on medical cannabis research, immediately moved FDA-approved marijuana products and state-licensed medical cannabis to Schedule III of the Controlled Substances Act, providing tax relief under Section 280E for qualifying operators while preserving strict controls on recreational use. An expedited DEA administrative hearing on broader rescheduling from Schedule I to III ran from June 29 to July 15, 2026; post-hearing briefs, including the DEA’s own argument that marijuana no longer meets Schedule I criteria due to accepted medical use, were filed in August, with the full transcript released in early September. The presiding ALJ’s recommendation to the Administrator remains pending without a statutory deadline, alongside ongoing D.C. Circuit litigation and a narrowed hemp definition effective November 2026. These steps shape trader assessments of timelines for any further federal action.
Polymarket डेटा का संदर्भ देने वाला प्रयोगात्मक AI-जनरेटेड सारांश। यह ट्रेडिंग सलाह नहीं है और इस बाज़ार के समाधान में कोई भूमिका नहीं निभाता। · अपडेट किया गया$802,588 वॉल्यूम
31 दिस, 2026
30 सितंबर
2%
31 दिसंबर
26%
$802,588 वॉल्यूम
30 सितंबर
$262 वॉल्यूम
2%
31 दिसंबर
$192,755 वॉल्यूम
26%
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), between market creation and September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by July 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.The April 2026 DOJ final order, issued under President Trump’s executive directive on medical cannabis research, immediately moved FDA-approved marijuana products and state-licensed medical cannabis to Schedule III of the Controlled Substances Act, providing tax relief under Section 280E for qualifying operators while preserving strict controls on recreational use. An expedited DEA administrative hearing on broader rescheduling from Schedule I to III ran from June 29 to July 15, 2026; post-hearing briefs, including the DEA’s own argument that marijuana no longer meets Schedule I criteria due to accepted medical use, were filed in August, with the full transcript released in early September. The presiding ALJ’s recommendation to the Administrator remains pending without a statutory deadline, alongside ongoing D.C. Circuit litigation and a narrowed hemp definition effective November 2026. These steps shape trader assessments of timelines for any further federal action.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
बाज़ार खुला: Feb 7, 2026, 5:04 PM ET
वॉल्यूम
$802,588समाप्ति तिथि
1 जन, 2027बाज़ार खुला
Feb 7, 2026, 5:04 PM ETरिज़ॉल्वर
0x65070BE91...This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), between market creation and September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by July 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.The April 2026 DOJ final order, issued under President Trump’s executive directive on medical cannabis research, immediately moved FDA-approved marijuana products and state-licensed medical cannabis to Schedule III of the Controlled Substances Act, providing tax relief under Section 280E for qualifying operators while preserving strict controls on recreational use. An expedited DEA administrative hearing on broader rescheduling from Schedule I to III ran from June 29 to July 15, 2026; post-hearing briefs, including the DEA’s own argument that marijuana no longer meets Schedule I criteria due to accepted medical use, were filed in August, with the full transcript released in early September. The presiding ALJ’s recommendation to the Administrator remains pending without a statutory deadline, alongside ongoing D.C. Circuit litigation and a narrowed hemp definition effective November 2026. These steps shape trader assessments of timelines for any further federal action.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
वॉल्यूम
$802,588समाप्ति तिथि
1 जन, 2027बाज़ार खुला
Feb 7, 2026, 5:04 PM ETरिज़ॉल्वर
0x65070BE91...The April 2026 DOJ final order, issued under President Trump’s executive directive on medical cannabis research, immediately moved FDA-approved marijuana products and state-licensed medical cannabis to Schedule III of the Controlled Substances Act, providing tax relief under Section 280E for qualifying operators while preserving strict controls on recreational use. An expedited DEA administrative hearing on broader rescheduling from Schedule I to III ran from June 29 to July 15, 2026; post-hearing briefs, including the DEA’s own argument that marijuana no longer meets Schedule I criteria due to accepted medical use, were filed in August, with the full transcript released in early September. The presiding ALJ’s recommendation to the Administrator remains pending without a statutory deadline, alongside ongoing D.C. Circuit litigation and a narrowed hemp definition effective November 2026. These steps shape trader assessments of timelines for any further federal action.
Polymarket डेटा का संदर्भ देने वाला प्रयोगात्मक AI-जनरेटेड सारांश। यह ट्रेडिंग सलाह नहीं है और इस बाज़ार के समाधान में कोई भूमिका नहीं निभाता। · अपडेट किया गया
बाहरी लिंक से सावधान रहें।
बाहरी लिंक से सावधान रहें।
अक्सर पूछे जाने वाले प्रश्न